NCT01294774

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and efficacy of KRP203 in clinically active subacute cutaneous lupus erythematosus patients, who have demonstrated inadequate response to standard treatment, such as antimalarials.

Conditions

• Subacute Cutaneous Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	KRP203 - 1.2mg
DRUG	Placebo to KRP203 - 1.2 mg

Timeline

• Start date: 2011-02-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2011-02-11
• Last updated: 2017-03-22

Locations

8 sites across 3 countries: Germany, Greece, Italy